Supplementary Methods
Transwell coculture system 6-well or 24-well dishes with polycarbonate membrane inserts (pore size of 3.0, Greiner, Germany) were used. Primary preadipocytes were seeded on six-well plates at a density 5x10 4 cells/well or on 24-well plates at a density of 1x10 4 cells and cultivated for 3 days in monocultures. EC were seeded on the upper side of a gelatine-coated transwell inserts at a density of 1x10 4 cells/well (24-well plate) or 5x10 4 cells/well (6-well plate) and also cultivated for 3 days.
After reaching confluence, filter membranes covered with EC were inserted into the six-well plates containing confluent RSFC on the bottom of the culture dish. By this construction, two culture compartments were created (PA-compartment and haEC-compartment). The same model was also used for the cocultivation of RSFC with PO. All cell types were cultured in same culture medium (Vasculife ENGS) because previous experiments showed that this medium supports both endothelial and RSFC growth. Thus, a potential medium gradient should be avoided between the two compartments. After 24 h, 48 h and 72 h, conditioned media from each compartment were collected separately and stored at -80°C. Finally, cells were lysed by lysis buffer (MachereyNagel, Düren, Germany, +ß-mercaptoethanol 1:100), and stored at -80°C.
Treatment conditions
Parts of mono-and cocultures were (pre)treated with 600 µg/ml fetuin-A (alpha-2-HSglycoprotein, Sigma, endotoxin <0.05 EU/µg or 0.005 ng/µg determined by ELISA Kit Hycult Biotech) ± 50 µM palmitic acid in BSA (Sigma) and several inhibitors.
Other parts were cultured in the same way but pretreated with the JNK inhibitor SP500125 (10 μmol/L), the p38MAPkinase inhibitor SB203580 (10 μmol/L), the MEK1/2 inhibitor PD98059
(10 μmol/L) and the NFκB inhibitor BAY11-7082 (1 μmol/L) 1 h before the addition of fetuin-A or 50 µM palmitic acid in BSA (Sigma) or Lipopolysaccharide (LPS) from S. minnesota R595 (5 ng/ml, Alexis). After 24h conditioned media from each compartment were collected separately and stored at -80°C. Monocultures were performed under exactly the same conditions but lacking the second cell type. Finally, cells were lysed and stored at -80°C, according to the manufacturer's instructions (lysis buffer +ß-mercaptoethanol 1:100, Macherey-Nagel, Düren, Germany). The primers and probes were designed using Universal Probe Library (Roche Applied Science).
Measurement of mRNA expression and primer
Gene-specific probes and primer pairs are the following:
ALCAM for GGAGGAATATGGAATCCAAGG, rev CTGAATTTACAGTATACCATCCAAGG
ICAM GCTGGAGCTGTTTGAGAACAC, rev CAAGTTGTGGGGGAGTCG
IL-6 for AGCTATGAACTCCTTCTCCACAA, rev GGTACTGGGGCAGGGAAG,
IL-8 for AGACAGCAGAGCACACAAGC, rev AGGAAGGCTGCCAAGAGAG,

MCP-1 for CTGCTCATAGCAGCCACCTT, rev GCACTGAGATCTTCCTATTGGTG,
HGF for GCATGTCCTCCTGCATCTC, rev TTCTTCTTTTCCTTTGTCCCTCT,
The amplification conditions were 5 min at 95°C, a cycle of 95°C for 10 sec, and 60°C for 30 sec and 72°C for 1 sec, for a total of 40 cycles. RNA was extracted using a kit (Nucleo Spin RNAII, Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions. For reverse transcription PCR, 1 μg of RNA was used with random hexamer primers and a cDNA synthesis kit (Transcriptor First Strand; Roche Diagnostics Deutschland GmbH, Mannheim, Germany) according to the manufacturer's instructions.
Immunohistochemical procedure
Immunohistochemical stainings of 4-μm-thick paraffin sections were performed using the OptiView Kit (Roche-Ventana, Multimer technology) which is a hapten-multimer system without biotin which minimizes background stainng. The following primary antibodies were used:
monoclonal mouse anti-human CD31 (1:100, clone JC70A, Dako Glostrup, Denmark), ployclonal rabbit anti-human CD206 (1:8,000, clone ab64693, Abcam, Cambridge, Massachusetts) and monoclonal mouse anti-human CD68 (1:3,000, clone KP-1, Dako).
Supplementary figures a b
Figure S1: FACS analysis: double labeling of (a) RSFC (b) and EC with antibodies against the adipocyte stem cell marker marker CD90, CD44, and CD105, and the EC-specific CD31 antigen. 
